WithSecure Corporation, Stock Exchange Release, 23 May 2025 at 9:30 EEST WithSecure Corporation – Managers’ Transactions – Siilasmaa WithSecure Corporation – Managers’ transactions – Siilasmaa ____________________________________________   Person subject to the notification requirement Name: Siilasmaa, Risto Position: Member of the Board/Deputy member Issuer: WithSecure Corporation LEI: 743700ATXLT0MFCHXT16   Notification type: INITIAL NOTIFICATION Reference number: 743700ATXLT0MFCHXT16_20250522123005_32 ____________________________________________   Transaction date: 2025-05-21 Venue not applicable Instrument type: SHARE ISIN: FI4000519228 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume: 33891 Unit price: 0.00 EUR   Aggregated transactions (1): Volume: 33891 Volume weighted...

WithSecure Corporation, Stock Exchange Release, 23 May 2025 at 9:30 EEST WithSecure Corporation – Managers’ Transactions – Kerkelä-Hiltunen WithSecure Corporation – Managers’ transactions – Kerkelä-Hiltunen ____________________________________________   Person subject to the notification requirement Name: Kerkelä-Hiltunen, Mervi Position: Member of the Board/Deputy member Issuer: WithSecure Corporation LEI: 743700ATXLT0MFCHXT16   Notification type: INITIAL NOTIFICATION Reference number: 743700ATXLT0MFCHXT16_20250522123005_37 ____________________________________________   Transaction date: 2025-05-21 Venue not applicable Instrument type: SHARE ISIN: FI4000519228 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume: 20335 Unit price: 0.00 EUR   Aggregated transactions (1): Volume:...

WithSecure Corporation, Stock Exchange Release, 23 May 2025 at 9:30 EEST WithSecure Corporation – Managers’ Transactions – Lehtiö WithSecure Corporation – Managers’ transactions – Lehtiö ____________________________________________   Person subject to the notification requirement Name: Lehtiö, Artturi Position: Member of the Board/Deputy member Issuer: WithSecure Corporation LEI: 743700ATXLT0MFCHXT16   Notification type: INITIAL NOTIFICATION Reference number: 743700ATXLT0MFCHXT16_20250522123005_38 ____________________________________________   Transaction date: 2025-05-21 Venue not applicable Instrument type: SHARE ISIN: FI4000519228 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume: 5366 Unit price: 0.00 EUR   Aggregated transactions (1): Volume: 5366 Volume weighted average...

WithSecure Corporation, Stock Exchange Release, 23 May 2025 at 9:30 EEST WithSecure Corporation – Managers’ Transactions – Martin WithSecure Corporation – Managers’ transactions – Martin ____________________________________________   Person subject to the notification requirement Name: Martin, Ciaran Position: Member of the Board/Deputy member Issuer: WithSecure Corporation LEI: 743700ATXLT0MFCHXT16   Notification type: INITIAL NOTIFICATION Reference number: 743700ATXLT0MFCHXT16_20250522123005_34 ____________________________________________   Transaction date: 2025-05-21 Venue not applicable Instrument type: SHARE ISIN: FI4000519228 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume: 16098 Unit price: 0.00 EUR   Aggregated transactions (1): Volume: 16098 Volume weighted...

 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE IT IS UNLAWFULTO DO SO Flutter announces the pricing of $1,000 million aggregate principal amount of 5.875% Senior Secured Notes due 2031, €550 million aggregate principal amount of 4.000% Senior Secured Notes due 2031 and £450 million aggregate principal amount of 6.125% Senior Secured Notes due 2031 DUBLIN and TORONTO, May 23, 2025 (GLOBE NEWSWIRE) — Flutter Entertainment plc (“Flutter“) (NYSE:FLUT; LSE:FLTR), today announced the pricing of an offering (the “Offering“) of $1,000 million aggregate principal amount of USD-denominated 5.875% senior secured notes due 2031, €550 million aggregate principal amount of EUR-denominated 4.000% senior secured notes due 2031, and £450 million aggregate principal amount...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 million, subscribed by a limited number of investors. This transaction strengthens the Company’s cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique...

ENDEAVOUR ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING 2025 London, 23 May 2025 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“the Company”) is pleased to announce that all resolutions at yesterday’s annual general meeting (“AGM”) were duly passed by shareholders. All resolutions were taken by poll and the results for the resolutions voted upon at the AGM are set out below:RESOLUTION VOTESFOR % FOR VOTESAGAINST % AGAINST TOTAL VOTES % OF ISC VOTED VOTESWITHHELDORDINARY RESOLUTIONS1. To receive the 2024 Annual Report 176,125,066 99.99% 24,217 0.01% 176,149,283 72.73% 180,9962. To re-elect Alison Baker as a Director 172,530,626 97.86% 3,781,331 2.14% 176,311,957 72.79% 18,3223. To re-elect Patrick Bouisset as a Director 176,089,288 99.87%...

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an initial focus on critically ill newborns and their parents. Whole genome sequencing can help diagnose babies with suspected genetic disorders, such as cystic fibrosis and sickle cell disease. This project will explore how this technology could become part of routine clinical practice for newborns, as well as its use in other research applications.Basel, 23 May 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’s recently unveiled next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology. This collaboration will focus on harnessing the power of the SBX technology...